home / stock / cmmb / cmmb quote
Last: | $0.70 |
---|---|
Change Percent: | -5.08% |
Open: | $0.62 |
Close: | $0.70 |
High: | $0.7 |
Low: | $0.62 |
Volume: | 29,623 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.7 | $0.62 | $0.7 | $0.7 | $0.62 | 29,623 | 04-18-2024 |
$0.59 | $0.6935 | $0.59 | $0.6949 | $0.579 | 48,946 | 04-17-2024 |
$0.6607 | $0.7 | $0.6607 | $0.74 | $0.6602 | 38,055 | 04-16-2024 |
$0.73 | $0.751 | $0.73 | $0.7697 | $0.72 | 50,262 | 04-15-2024 |
$0.7698 | $0.75 | $0.7698 | $0.79 | $0.75 | 11,602 | 04-12-2024 |
$0.76 | $0.79 | $0.76 | $0.79 | $0.755 | 38,253 | 04-11-2024 |
$0.79 | $0.79 | $0.79 | $0.8 | $0.775 | 13,545 | 04-10-2024 |
$0.79 | $0.79 | $0.79 | $0.8 | $0.78 | 15,688 | 04-09-2024 |
$0.7906 | $0.7999 | $0.7906 | $0.7999 | $0.775 | 73,529 | 04-08-2024 |
$0.8 | $0.7695 | $0.8 | $0.8 | $0.7695 | 35,690 | 04-05-2024 |
$0.78 | $0.79 | $0.78 | $0.8 | $0.7603 | 43,618 | 04-04-2024 |
$0.807 | $0.78 | $0.807 | $0.807 | $0.7476 | 56,917 | 04-03-2024 |
$0.762 | $0.768 | $0.762 | $0.77 | $0.74 | 16,400 | 04-02-2024 |
$0.7712 | $0.78 | $0.7712 | $0.7912 | $0.7601 | 34,158 | 04-01-2024 |
$0.779 | $0.77 | $0.779 | $0.78 | $0.7501 | 28,961 | 03-29-2024 |
$0.779 | $0.77 | $0.779 | $0.78 | $0.7501 | 28,961 | 03-28-2024 |
$0.77 | $0.7433 | $0.77 | $0.78 | $0.7 | 48,121 | 03-27-2024 |
$0.749 | $0.73 | $0.749 | $0.766899 | $0.698 | 44,367 | 03-26-2024 |
$0.727 | $0.749 | $0.727 | $0.7999 | $0.7013 | 295,462 | 03-25-2024 |
$0.7701 | $0.7701 | $0.7701 | $0.7889 | $0.751 | 27,537 | 03-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Chemomab Therapeutics Ltd. Company Name:
CMMB Stock Symbol:
NASDAQ Market:
—Longitudinal Study of a 200+ Real-World Patient Cohort Further Validates CCL24 as a Novel Target for Systemic Sclerosis (SSc), Showing that It is Associated with Disease Severity Across the Fibrotic and Vascular Manifestations of SSc— TEL AVIV, Israel, April 18, 2024 (G...
—"Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis" Will Feature Clinical, Academic and Patient Advocacy Leaders Discu...
—“Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis” Will Feature Clinical, Academic and Patient Advocacy Leaders Discussing PSC Disease Management and Evolving Views on Clinical Development— TEL AVIV, Israel, April 02, 2024 (GLOBE ...